Spain is sending back faulty coronavirus tests to China that were supposed to be replacements for the first faulty batch
Spainfound faults in a batch of coronavirustests sent by a Chinese company, which had been sent as a replacement for a first batch that the country received and then returned.
- Spain says it now wants a refund for its entire order of 640,000 tests after finding the tests in both batches weren't sensitive enough to consistently detect the virus, El País newspaper reported.
- The faults in the first batch from Bioeasy, the Chinese company, came at a crucial time in the county's fight against the outbreak. Now more than 21,000 people have died in the country.
Chinasaid Bioeasy was not an approved retailer, and opened an investigation into it last month. Other countries have reported problems with equipment bought from other Chinese companies.
- Visit Business Insider's homepage for more stories.
Spain has found faults in a second batch of coronavirus tests bought from a Chinese company that was intended to replace a first batch of faulty tests.Spain's health ministry confirmed to El País newspaper that it is trying to get a refund for the tests that it bought from Bioeasy, a Chinese company, after testing a sample and discovering that they were not sensitive enough to detect enough coronavirus cases.
But in light of the issues with the new tests, Spain now wants a refund for the entire order of 640,000 tests. It did not say how much the order is worth.
Spain has now also abandoned its plan to use rapid tests, according to El País, relying instead on tests that look for antibodies in recovered people and on a more expensive form of looking for the virus in peoples' DNA.
The first batch of tests could not consistently identify positive coronavirus casesEl País reported in March that health authorities examined the rapid tests, which are supposed to give an accurate result within minutes, and realized that they were only correctly identifying people with the virus 30% of the time. Sources told the newspaper at the time that the tests should have had a sensitivity of more than 80%, which is the standard the US Centers for Disease Control and Prevention requires for rapid influenza tests.
Spain separately ordered 432 million euros ($460 million) worth of medical equipment from China, including 5.5 million tests.
The first faulty batch arrived while Spain was battling the worst of its crisis and its deaths had soared to 4,000, becoming at the time the world's second-most infected country after Italy.Spain's infections are still the second-highest in the world. More than 21,000 people have now died in the country, and its more than 208,000 infections are second only to the US.
But its number of new infections has slowed, its death rate has halved, and its parliament is discussing steps to slowly start to reopen the country.
China has distanced itself from Bioeasy, saying it is not an approved vendorThe Chinese Embassy in Spain tweeted after reports of issues with the first batch sent to Spain that Bioeasy had not been given a license from China's National Medical Products Administration to sell its products.
Spain's government said that Bioeasy had permission to export to the EU, and said it had bought the tests from a Spanish distributor rather than directly from Bioeasy, El País reported.China has since cracked down on exports of medical equipment, saying any company exporting coronavirus tests needs to obtain a registration certificate from the National Medical Products Administration.
China also opened an investigation into Bioeasy last month after reports of the first batch of faulty tests.The pandemic has resulted in a boom in medical equipment production in China, with 38,000 new companies in China registering to make or trade face masks in 2020 so far, as companies pivot their output during a global mask shortage.
But other countries have also rejected medical equipment from Chinese companies, citing faults.which did not work. The New York Times reported that these came from two companies, AllTest Biotech and Wondfo Biotech.
India has also reported malfunctions in the antibody tests it ordered from China, and has paused the use of some rapid tests.Read the original article on Business Insider
- Byju's most valuable startup in India and 11th in the world with a valuation of $16.5 billion
- India witnesses decline in daily COVID-19 cases with 80,834 fresh cases in last 24 hours, lowest since April 1
- Delhi reports its lowest daily COVID-19 cases in 104 days, records 213 single day COVID-19 cases
- Here’s how to recharge your Reliance Jio on WhatsApp
- India may classify Bitcoin as an asset class, but that may not solve the underlying problem